Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Would you use cetuximab or panitumumab to treat a patient with stage IV colon cancer who is KRAS/NRAS wild-type but has a PIK3CA mutation in tumor tissue?
Related Questions
For a patient with metastatic colon cancer which is MSI-H/dMMR and BRAF V600E+, what would be your preferred first line treatment?
Are there any adverse risk factors in stage I colon cancer that would warrant ctDNA testing?
What are your top takeaways in GI Cancers from ASCO 2025?
How do you best incorporate use of filgrastim/pegfilgrastim in capecitabine based regimens?
In a patient with metastatic colorectal cancer to the lung and liver, is there a role for liver directed therapy if the lung is not amenable to local therapy?
What is your approach to TNT sequencing for locally advanced rectal primaries with low volume metastatic disease to liver?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
What is the data to guide salvage radiation to a patient with recurrence anal cancer to the lymph node after an initial definitive chemoradiation?
What would your approach be for a locally advanced head and neck cancer diagnosed concurrently with a mid-esophageal cancer?
How do you approach patients with partially occlusive thrombus in the splenic vein posterior to the pancreatic cancer lesion?
